Patient characteristics
| Group C (n=10) | Group TLow (n=27) | Group THigh (n=23) | |
|---|---|---|---|
| Data are mean (SD) or number of patients. *p<0.05 v control; †p<0.05 v group TLow (pretraining slope of minute ventilation relative to carbon dioxide production (V̇E/V̇Co2) <30). | |||
| ACE, angiotensin converting enzyme; Group C, control group; FEV1, forced expiratory volume in one second; Peak V̇o2, peak oxygen uptake; THigh, pretraining V̇E/V̇Co2 ≥30; Tlco, carbon monoxide transfer factor; VC, vital capacity. | |||
| Age (years) | 57 (13) | 58 (11) | 63 (7) |
| Men/women | 7/3 | 22/5 | 22/1 |
| Ejection fraction (%) | 46 (9) | 45 (8) | 41 (10) |
| Forrester’s subset II or greater | 2 | 3 | 3 |
| Drug administration | |||
| ACE inhibitors | 8 (80%) | 16 (59%) | 14 (61%) |
| β Blockers | 4 (40%) | 2 (7%) | 7 (30%) |
| Digoxin | 0 (0%) | 0 (0%) | 3 (13%) |
| Spirometry | |||
| VC (%predicted) | 105 (13) | 102 (12) | 97 (13) |
| FEV1 (%predicted) | 82 (6) | 86 (11) | 80 (11) |
| Tlco (%predicted) | 102 (17) | 105 (17) | 96 (26) |
| Peak V̇o2 (ml/kg/min) | 24 (5) | 23 (5) | 19 (4)*† |
| V̇E/V̇Co2 slope | 30 (10) | 25 (3)* | 35(5)*† |